How many fine-needle aspiration (FNA) passes are required for the Interpace Thyramir test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Interpace ThyraMIR FNA Pass Requirements

For Interpace ThyraMIR testing of thyroid nodules, a minimum of 2 dedicated FNA passes should be obtained, though 3-4 passes are recommended to optimize specimen adequacy and molecular testing success.

Specimen Requirements for Molecular Testing

The available evidence does not provide specific manufacturer guidelines for ThyraMIR pass requirements in the provided materials. However, thyroid FNA molecular testing requirements can be extrapolated from general thyroid FNA best practices and molecular testing studies:

Minimum Pass Recommendations

  • Without on-site adequacy assessment: Perform at least 3 needle passes per thyroid nodule to maximize diagnostic adequacy 1, 2
  • With rapid on-site adequacy assessment (ROSAA): The number of passes can be adjusted based on real-time cytology evaluation, with studies showing mean passes of 3.2-3.8 achieving adequate specimens 1, 2

Evidence Supporting Pass Numbers

  • Studies of thyroid FNA demonstrate that adequacy rates improve with increasing passes: specimen adequacy reaches 90.1% after the first pass, 98.1% after two passes, and approaches 100% after three passes 3
  • One study specifically evaluating molecular testing (ThyGenX/ThyraMIR) at an institution showed successful risk stratification, though the specific number of passes dedicated to molecular testing was not explicitly stated 4
  • The mean number of needle punctures necessary for adequate thyroid specimens ranges from 3.2 to 5.4 depending on operator experience and technique 1

Practical Approach

Standard Protocol

  • Perform 3-4 total FNA passes for thyroid nodules requiring molecular testing 1, 2
  • Dedicate at least 2 passes specifically for molecular analysis if splitting samples between cytology and molecular testing 5
  • If ROSAA is available, use it to confirm adequacy and potentially reduce unnecessary passes 1, 2

Factors Affecting Adequacy

  • Nodule characteristics: Cystic nodules have significantly higher inadequacy rates (15%) compared to solid nodules (1%) and may require additional passes 1
  • Increased intranodular vascularization: Associated with lower diagnostic yield (51.8% adequacy) and may necessitate additional passes 2
  • Operator experience: Less experienced operators may require more passes to achieve adequate specimens 1

Important Caveats

  • The specific manufacturer requirements for ThyraMIR should be confirmed directly with Interpace Diagnostics, as commercial molecular tests may have proprietary specimen requirements not detailed in published literature
  • Contact the processing laboratory before the procedure to confirm their specific collection requirements, including number of passes, collection media, and handling protocols 5
  • Consider performing one additional pass beyond the minimum if the nodule has challenging characteristics (cystic, highly vascular, or small size <1 cm) 1, 2, 6

References

Guideline

Diagnostic Yield of EBUS-TBNA

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Needle size and sample adequacy in ultrasound-guided biopsy of thyroid nodules.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.